GAVISCON (aluminum hydroxide; magnesium trisilicate) by Sanofi. Approved for heartburn acid indigestion sour stomach upset stomach associated with these symptoms. First approved in 1983.
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
Gaviscon is an oral antacid combination of aluminum hydroxide and magnesium trisilicate approved in 1983 for relief of heartburn, acid indigestion, sour stomach, and associated upset stomach symptoms. It works through direct neutralization of gastric acid. The chewable tablet formulation provides rapid symptomatic relief in the OTC antacid market.
Product approaching loss of exclusivity with moderate competitive pressure (30), indicating potential team restructuring and shift toward generic or brand transition strategies.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects
Scintigraphy Study to Compare the Antireflux Activity of the Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects
Worked on GAVISCON at Sanofi? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Gaviscon offers limited career growth opportunities given its mature, LOE-approaching status and zero linked job openings. Roles available are primarily in brand maintenance, retail partnerships, and commercial efficiency rather than innovation or market expansion.